NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending natalizumab RRMS treatment options, including the originator biologic and its biosimilar, for adults with highly active relapsing-remitting multiple sclerosis (RRMS) who have not responded to at least one prior disease-modifying therapy (DMT) and for whom cladribine is unsuitable. This decision expands access to natalizumab for an thousands of patients in the UK, including those with highly active disease characterized by ongoing relapses or imaging evidence of activity despite initial treatments. The guidance specifies subcutaneous natalizumab originator (Tysabri by Biogen) and intravenous natalizumab biosimilar (Tyruko by Sandoz) as options, while ruling out intravenous natalizumab originator due to cost-effectiveness concerns, thereby enhancing patient choice through equivalent clinical outcomes at potentially lower costs via biosimilars. For detailed insights on this recommendation, see NICE’s official announcement.
Proven Relapse Reduction in Tough RRMS Cases
Clinical evidence from randomized controlled trials (RCTs), such as AFFIRM and REVEAL, demonstrates natalizumab’s efficacy in reducing annualized relapse rates (ARR) and confirmed disability progression (CDP) compared to placebo and alternatives like fingolimod, with indirect comparisons via network meta-analysis (NMA) suggesting comparable performance to high-efficacy DMTs including ocrelizumab, ofatumumab, and ublituximab in RRMS populations.
In highly active RRMS, observational data from the TOP study indicate a 90% ARR reduction post-natalizumab initiation, particularly benefiting patients with high lesion loads or enhancing lesions on magnetic resonance imaging (MRI), where natalizumab binds to immune cells to prevent central nervous system infiltration. The NMA, encompassing 42 RCTs for the broader RRMS group and a subgroup for highly active disease, confirms no significant differences in serious adverse events or treatment discontinuation rates across these therapies, supporting natalizumab RRMS treatment as an equivalent option without direct head-to-head trials, though uncertainties arise from study heterogeneity and the exclusion of lower-efficacy comparators like interferons.
Modeling Real-World RRMS Progression for Approval
NICE’s evaluation employed a discrete-event simulation (DES) model informed by real-world data from the UK MS Register (2017–2024) to capture RRMS natural history, incorporating events like relapse, Expanded Disability Status Scale (EDSS) progression, and transition to secondary progressive MS, with treatment effects derived from NMA-applied relative risks to baseline rates from trials such as AFFIRM. This approach contrasts with prior Markov models by enabling treatment sequencing—modeling third- and fourth-line options like ocrelizumab or siponimod based on MS Register usage—and addressing progression dynamics, such as limiting secondary progressive MS transitions to EDSS scores above 4.5 to align with clinical realities of slower disease advancement under modern DMTs. Utility values from the UK MS Survey and mortality rates with EDSS-specific adjustments further grounded the economic analysis, revealing natalizumab’s cost-effectiveness at £20,000–£30,000 per quality-adjusted life year (QALY) when cladribine-ineligible, supported by confidential pricing agreements that enhance value.
Biosimilar Savings Unlock Broader RRMS Access
The guidance highlights natalizumab’s value which delivers identical clinical benefits at reduced costs—evidenced by Tyruko’s lower list price (£1,017 vs. £1,130 per dose)—enabling expanded access for highly active RRMS patients while optimizing National Health Service (NHS) resource allocation through smarter spending on equivalents to originators. In market access terms, this recommendation facilitates reimbursement, addressing unmet needs in refractory cases, particularly where cladribine contraindications (e.g., pregnancy planning) limit options, potentially reducing disability accrual and long-term care costs amid trends toward high-efficacy DMT sequencing. Reflecting industry shifts toward biosimilars, this fosters outcomes research by researching uncaptured benefits like natalizumab RRMS treatment’s pregnancy safety—unlike ocrelizumab or cladribine—thus supporting personalized reimbursement pathways and enhancing patient-centered value in RRMS management without inflating overall expenditure.
